“Gabapentin is sort of the poster child for limited evidence of benefit.” — Donovan Maust, MD, MS, of the University of Michigan in Ann Arbor, on a study of polypharmacy in patients with dementia.
“There’s no unseeing and unliving what they lived.” — Kate Judge, executive director of the American Nurses Foundation, on the impact of the pandemic on nurses’ mental health.
“I was blown away by these results.” — Sharon Hillier, PhD, of the University of Pittsburgh School of Medicine, discussing how a novel drug reduced viral load in treatment-experienced HIV patients on failing drug regimens.
“I think for a lot of people, especially Black people, we’re not used to getting gifts from the kindness of other people’s hearts. We’re used to doing things ourselves and prioritizing others.” — Farrah-Amoy Fullerton, a fourth-year med student at the University of Alabama at Birmingham, on the Twitter trend #MedGradWishList.
“But to enroll and then undermine it for personal benefit is a small act of scientific sabotage that should be strongly condemned.” — Steven Goodman, MD, PhD, of Stanford University, discussing “self-unblinding” in COVID vaccine trials.
“When aging and other risk factors for dementia start accumulating, [individuals with schizophrenia] might cross a threshold for dementia diagnosis much sooner.” — T. Scott Stroup, MD, MPH, of Columbia University, on finding a significantly elevated prevalence of dementia among individuals of a certain age with schizophrenia.